Search

Biochanin A

Biochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).

Albinterferon Alfa-2B

In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.

INCB7839

It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients. … INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways.

Biomed 101

Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid.

Imazaquin

2,5-di-tert-butylhydroquinone

Sibrotuzumab

Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

Amibegron

Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.

Morphine glucuronide

AT9283

AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. … It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.